{"title":"Tralokinumab for the treatment of atopic dermatitis","authors":"S. Chaplin","doi":"10.1002/psb.1995","DOIUrl":null,"url":null,"abstract":"Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.1995","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
